focus -WSS

focus

author：comprehensive 2025-10-02 22:28:16 - browse：8

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

WSS

Custom gene therapy hints at new path for rare disease treatments

STAT Virtual Event: The State of Biosimilars: What to Watch

Readout LOUD podcast: Live from the 2023 STAT Summit

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

The problems with dementia villages

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

entertainment

focus

Wikipedia

How one medical school became remarkably diverse

Custom gene therapy hints at new path for rare disease treatments

Medicare details structure of new drug price negotiation program

CZI to create biohub to build anti

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Readout Newsletter: Biotech news today

Drug repurposing or repositioning? The language matters

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Anesthesiologist group: stop taking Ozempic before surgery

Questions loom on AstraZeneca cancer drug as safety concerns ebb

entertainment

Questions loom on AstraZeneca cancer drug as safety concerns ebb

ADCs take center stage as promising cancer treatments

Cosmetics set for new safety regulation. Why the industry is on board

STAT Summit: The economic case for universal basic health care

Sanofi seeks simpler, safer CRISPR sickle cell cure

Startup Neumora takes a novel depression drug to Phase 3

knowledge

hotspot

hotspot

hotspot